Carbocysteine

Instructions for use of the drug

Structure

Active ingredient: сarbocisteine;

Bronchomucin 2% 1 ml of syrup contains 20 mg of carbocysteine;

Bronchomucin 5% 1 ml of syrup contains 50 mg of carbocysteine;

Excipients: sodium hydroxide, sodium saccharin, propylene glycol, sucrose, methylparaben (E 218), caramel, yellow sunset FCF (E-110), purified water.

Dosage form

Syrup.

Basic physical and chemical properties: light yellow syrup with caramel flavor.

Pharmacotherapeutic group

Means used for cough and colds. mucolytic agents.

PBX code R05C B03.

Pharmacological properties

Pharmacodynamics

Carbocysteine ​​affects the gel phase of the mucus of the respiratory tract by breaking the disulfide bridges of glycoproteins, causing thinning of the excessively viscous secretion of the bronchi, and helps to eliminate sputum.

The mucoregulatory effect of carbocysteine ​​is associated with the activation of sialic transferase, an enzyme of goblet cells of the bronchial mucosa. Carbocysteine ​​normalizes the proportion of acidic and neutral sialomucins of bronchial secretion, restores its viscosity and elasticity. It activates the activity of ciliated epithelium and improves mucociliary clearance. It promotes the regeneration of the mucous membrane of the respiratory tract, normalizes its structure, reduces goblet cell hyperplasia and, as a result, reduces mucus production. Restores the secretion of immunologically active IgA (specific protection) and the number of sulfhydryl groups of mucus components (non-specific protection). It has an anti-inflammatory effect due to the kinin-inhibiting activity of sialomucins, reducing swelling and bronchial obstruction.

Pharmacokinetics

When administered, carbocysteine ​​is rapidly absorbed. The peak concentration of the active substance in blood plasma is reached after 2 hours. Bioavailability is low - less than 10% of the administered dose (due to intensive metabolism in the digestive tract and the effect of the first passage through the liver).

Carbocysteine ​​and its metabolites are excreted mainly in the urine. The half-life is about 2 hours.

Clinical characteristics

Indications

Treatment of symptoms of disorders of bronchial secretion and sputum excretion, especially in acute bronchopulmonary diseases, for example, in acute bronchitis; with exacerbations of chronic diseases of the respiratory system.

Contraindications

• An allergic reaction to any of the components of the drug in history (especially to methyl paraben or other salts of parahydroxybenzoate); peptic ulcer of the stomach and duodenum during exacerbation; i trimester of pregnancy due to insufficient data on teratogenic and embryotoxic effects of the drug.

Special security measures

Do not use with drugs that inhibit cough, and drugs that reduce secretion (atropine group).

Treatment should be reviewed if there is no effect or worsening of the symptoms of the disease.

Careful monitoring by a doctor is necessary when purulent sputum is excreted, high temperature.

The drug should be used with caution during the treatment of patients with a history of gastric ulcer or duodenal ulcer.

The drug contains sucrose, so patients with rare hereditary forms of galactose intolerance, congenital lactose deficiency or glucose-galactose malabsorption syndrome should avoid taking the drug.

Please note that 5 ml of 2% syrup contains 1.75 g of sugar, and 15 ml of 5% syrup contains 5.25 g of sugar.

The drug contains methyl paraben, as well as the sunset yellow colorant FCF (E 110), therefore, the content of these components can cause an allergic reaction (which may occur over time).

Interaction with other drugs and other types of interactions

During treatment with carbocysteine, antitussive drugs and drugs that suppress bronchial secretion should not be used. the drug increases the effectiveness of glucocorticoid (mutually) and antibiotic therapy.

Application features

Use during pregnancy and lactation.

During animal studies, no teratogenic effects were detected. To date, there have been no reports of teratogenic effects in the post-registration period. There is no data on the intake of carbocysteine ​​in breast milk.

The drug is contraindicated in the first trimester of pregnancy.

In the II and III trimester of pregnancy and the period of breastfeeding, the drug is used after a careful assessment of the ratio of the benefit to the mother / risk to the fetus (child), which is determined by the doctor.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms.

Does not affect.

Dosage and administration

Bronchomucin 2% is recommended for the treatment of children aged 2 to 15 years,

Bronchomucin 5% - for the treatment of adults and children from 15 years.

The maximum single dose for children is 100 mg of carbocysteine.

The duration of treatment is not more than 8-10 days; for children - no more than 5 days.

Children.

Treatment of children is carried out under the supervision of a doctor.

Bronchomucin 2% is used to treat children 2-15 years old. Bronchomucin 5% - for children from 15 years.

Overdose

Symptoms: stomach pain, nausea, diarrhea.

Treatment: stop taking the drug and consult a doctor.

Adverse Reactions

Very rarely possible digestive disorders, nausea, vomiting, stomach pain. the drug contains methylparaben, therefore, in rare cases, allergic reactions are possible, including angioedema, itching and rash (which may occur over time). in case of side effects, it is recommended to consult a doctor, it may be necessary to reduce the dose or stop taking the drug.

Shelf life.

3 years.

Storage conditions

Store in the original packaging out of the reach of children at a temperature not exceeding 25 ° C

Packaging

120 ml of syrup in a glass bottle in a cardboard box.

Holiday Category

Over the counter.